Glow LifeTech (FRA:9DO) ROE %: -8.02% (As of Mar. 2026)


What is Glow LifeTech ROE %?

Glow LifeTech FRA:9DO +14.71% ROE % is -8.02% as of Mar. 2026. The stock has 1 warning sign investors should review. Among 1,252 Biotechnology companies, Glow LifeTech ranks better than 61.26% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Glow LifeTech's annualized net income for the quarter that ended in Mar. 2026 was €-0.15 Mil. Glow LifeTech's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was €1.85 Mil. Therefore, Glow LifeTech's annualized ROE % for the quarter that ended in Mar. 2026 was -8.02%.

The historical rank and industry rank for Glow LifeTech's ROE % or its related term are showing as below:

FRA:9DO' s ROE % Range Over the Past 10 Years
Min: -1755.8   Med: -345.29   Max: -20.69
Current: -20.69

During the past 7 years, Glow LifeTech's highest ROE % was -20.69%. The lowest was -1,755.80%. And the median was -345.29%.

FRA:9DO's ROE % is ranked better than
61.26% of 1252 companies
in the Biotechnology industry
Industry Median: -38.145 vs FRA:9DO: -20.69

Glow LifeTech  (FRA:9DO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-0.148/1.8465
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.148 / 1.624)*(1.624 / 2.564)*(2.564 / 1.8465)
=Net Margin %*Asset Turnover*Equity Multiplier
=-9.11 %*0.6334*1.3886
=ROA %*Equity Multiplier
=-5.77 %*1.3886
=-8.02 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-0.148/1.8465
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-0.148 / -0.148) * (-0.148 / -0.18) * (-0.18 / 1.624) * (1.624 / 2.564) * (2.564 / 1.8465)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.8222 * -11.08 % * 0.6334 * 1.3886
=-8.02 %

Note: The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Glow LifeTech ROE % Related Terms


Glow LifeTech ROE % Historical Data

* Premium members only.

The historical data trend for Glow LifeTech's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glow LifeTech ROE % Chart

Glow LifeTech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE %
Get a 7-Day Free Trial -719.36 -95.03 -1,585.40 -349.90 -22.52

Glow LifeTech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.93 -61.82 -18.56 0.26 -8.02

FRA:9DO vs VRTX, REGN, ALNY: ROE % Comparison

For the Biotechnology subindustry, Glow LifeTech's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glow LifeTech ROE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Glow LifeTech's ROE % distribution charts can be found below:

* The bar in red indicates where Glow LifeTech's ROE % falls into.



Glow LifeTech ROE % Calculation

Glow LifeTech's annualized ROE % for the fiscal year that ended in Dec. 2025 is calculated as

ROE %=Net Income (A: Dec. 2025 )/( (Total Stockholders Equity (A: Dec. 2024 )+Total Stockholders Equity (A: Dec. 2025 ))/ count )
=-0.383/( (1.723+1.678)/ 2 )
=-0.383/1.7005
=-22.52 %

Glow LifeTech's annualized ROE % for the quarter that ended in Mar. 2026 is calculated as

ROE %=Net Income (Q: Mar. 2026 )/( (Total Stockholders Equity (Q: Dec. 2025 )+Total Stockholders Equity (Q: Mar. 2026 ))/ count )
=-0.148/( (1.678+2.015)/ 2 )
=-0.148/1.8465
=-8.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. ROE % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of -8.02% mean?
Glow LifeTech (FRA:9DO) has a ROE % of -8.02% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Glow LifeTech and its competitors. According to the industry distribution chart, Glow LifeTech ranks #485 out of 1252 companies in the Biotechnology industry, placing it in the top 38.7%.
Is Glow LifeTech's ROE % too high?
Glow LifeTech's current ROE % is -8.02%. Based on the distribution chart, Glow LifeTech ranks #485 out of 1252 companies in the Biotechnology industry, which is above the industry midpoint.
How does Glow LifeTech's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Glow LifeTech ranks #485 out of 1252 companies for ROE %. This puts Glow LifeTech in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Glow LifeTech and its competitors. Glow LifeTech's current ROE % is -8.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glow LifeTech stock overvalued right now?
Glow LifeTech (FRA:9DO) has a current ROE % of -8.02%. The current ROE % is -8.02%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Glow LifeTech (FRA:9DO), the current ROE % is -8.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Glow LifeTech Business Description

Address 65 International Boulevard, Suite 103, Etobicoke, ON, CAN, M9W 6L9
Glow LifeTech Corp is a biotechnology company engaged in the business of secondary processing of ingredients to produce micellized materials from certain vitamins, nutraceuticals, and cannabis extracts. Its plant-based MyCell Technology delivery system transforms poorly absorbed natural compounds into enhanced water-compatible concentrates, unlocking the full healing potential of natural active compounds.